For decades, hot flashes have been the subject of jokes or dismissed as a temporary inconvenience.

But in the last few years, drug companies have started to take the condition seriously.

Two new medications — one approved by the FDA in 2023, another in October — treat hot flashes by blocking receptors in the brain that can cause the body’s thermostat to go awry. Unlike the primary treatments for hot flashes, these drugs are not hormonal, meaning that they can be taken by women with a history of breast cancer, strokes or other risk factors.

“For people who cannot use hormones or who choose not to use hormones, it’s a game changer for these patients,” said Sarah Richina, director of the UPMC Magee-Womens Midlife Health Center. “We can now tell patients who can’t use estrogen that we have really good options that are evidence-based and effective.”

Advertise with us

Hot flashes, also called vasomotor symptoms, are sudden, discrete episodes in which a woman starts at a normal temperature and has a rush of heat. Lasting about one to five minutes, they’re experienced by up to 80% of women during menopause. The episodes can vary in severity from just a flush of warmth to such an intense heat that women need to stop what they are doing. They can occur day or night, and one of the most detrimental health effects from hot flashes are the “night sweats” sleep disruptions they cause.

Although hot flashes were once thought to last only a year or two, researchers now believe that they can endure for seven to 10 years.

“It’s not an insignificant amount of time,” said Helana Pietragallo, an obstetrician/gynecologist with Allegheny Health Network. “It’s something like a decade of your life.”

Hot flashes are caused by hormonal changes in menopause and perimenopause. A lack of estrogen causes certain receptors in the brain’s hypothalamus, called KNDy neurons, to become overstimulated, making them hypersensitive to heat cues.

The two new drugs, fezolinetant (brand name Veozah) and elinzanetant (brand name Lynkuet) work by blocking those receptors to make them less sensitive. The drugs work within weeks and were both able to reduce the incidence of hot flashes significantly more than a placebo. The U.S. Food and Drug Administration approved Veozah in May 2023 and approved Lynkuet in October 2025.

Advertise with us

Lynkuet became available to consumers Nov. 13, per a Bayer spokesperson.

One clinical trial of Lynkuet gave 600 post-menopausal women either the drug or a placebo and found that those taking Lynkuet saw a 73% reduction in the frequency and severity of hot flashes after 12 weeks. A clinical trial of Veozah found that about 81% to 95% of participants receiving the drug experienced a 50% or greater reduction in hot flashes from their baselines, with symptoms starting to improve within the first week of treatment.

Both are oral medications taken once daily, and patients on both medications need to be monitored for elevated liver readings.

Prior to the approval of these medications, women who could not or did not want to take hormones used several medications off-label that have been found to be effective in reducing hot flashes.

Those included paroxetine, an antidepressant, and gabapentin, which is designed to treat nerve pain. Women with a history of breast cancer who are taking the drug tamoxifen are advised to avoid paroxetine, however.

Advertise with us

Other non-hormonal treatments for hot flashes shown to be effective include weight loss, hypnosis and cognitive behavioral therapy.

The new drugs, Veozah and Lynkuet, are more targeted than previous non-hormonal remedies and likely more effective.

The emergence of the drugs reflect new attitudes toward menopause, driven in part by conversations on social media and by a recognition that menopause is a treatable condition.

“People are not happy with the status quo of accepting that they have to live with these symptoms that can be disruptive and problematic,” said Pietragallo. “The taboo that is associated with menopause and perimenopause is going away.”